Related Experiment Video
Updated: Oct 16, 2025

Tracking Drug-induced Changes in Receptor Post-internalization Trafficking by Colocalizational Analysis
Published on: July 3, 2015
Alternative Pre-mRNA Splicing of the Mu Opioid Receptor Gene, OPRM1: Insight into Complex Mu Opioid Actions
Shan Liu1, Wen-Jia Kang1, Anna Abrimian1
1Department of Anesthesiology, Rutgers New Jersey Medical School, Newark, NJ 07103, USA.
Abstract:
Most opioid analgesics used clinically, including morphine and fentanyl, as well as the recreational drug heroin, act primarily through the mu opioid receptor, a class A Rhodopsin-like G protein-coupled receptor (GPCR). The single-copy mu opioid receptor gene, OPRM1, undergoes extensive alternative splicing, creating multiple splice variants or isoforms via a variety of alternative splicing events. These OPRM1 splice variants can be categorized into three major types based on the receptor structure: (1) full-length 7 transmembrane (TM) C-terminal variants; (2) truncated 6TM variants; and (3) single TM variants. Increasing evidence suggests that these OPRM1 splice variants are pharmacologically important in mediating the distinct actions of various mu opioids. More importantly, the OPRM1 variants can be targeted for development of novel opioid analgesics that are potent against multiple types of pain, but devoid of many side-effects associated with traditional opiates. In this review, we provide an overview of OPRM1 alternative splicing and its functional relevance in opioid pharmacology.
Insights
Mu opioid receptor (OPRM1) gene splicing creates variants impacting opioid drug actions. Targeting these OPRM1 variants offers potential for developing effective pain relievers with fewer side effects.
Area of Science:
- Pharmacology
- Molecular Biology
- Genetics
Background:
- Mu opioid receptor (MOR) is a key target for opioid analgesics like morphine and fentanyl.
- The MOR gene (OPRM1) exhibits extensive alternative splicing, producing diverse receptor variants.
- These OPRM1 variants differ in structure, including full-length, truncated 6TM, and single TM forms.
Purpose of the Study:
- To review the alternative splicing of the OPRM1 gene.
- To discuss the functional relevance of OPRM1 splice variants in opioid pharmacology.
- To highlight the therapeutic potential of OPRM1 variants for novel pain management strategies.
Main Methods:
- Literature review of OPRM1 alternative splicing.
- Analysis of structural classifications of OPRM1 variants.
- Examination of pharmacological evidence for OPRM1 variant functions.
Main Results:
- OPRM1 gene undergoes extensive alternative splicing, generating multiple functional isoforms.
- OPRM1 splice variants exhibit distinct pharmacological properties.
- Evidence suggests OPRM1 variants mediate differential effects of various mu opioids.
Conclusions:
- OPRM1 splice variants are crucial in determining opioid efficacy and side effect profiles.
- Targeting specific OPRM1 variants could lead to the development of safer and more potent analgesics.
- Understanding OPRM1 splicing is vital for advancing opioid-based pain therapeutics.
Related Concept Videos
Opioid Receptors: Overview
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
RNA Splicing
Analgesia and Pain Management
Nonsense-mediated mRNA Decay
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...
What is Gene Expression?

